Recruiting- Phase 2
ClinicalTrials.gov IDNCT06635148
SponsorJanssen Research & Development, LLC
Information Provided byJanssen Research & Development, LLC Clinical Trial
Study Start (Actual)2024-09-19
Primary Completion (Estimated) 2029-08-24
Study Completion (Estimated)2030-06-27
Enrollment (Estimated)311
Study Type Interventional
Last Update Posted2025-09-12
Study Overview
Brief Summary
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
To learn more, visit ClinicalTrials.gov
Contact info:
Study Contact
Name Study Contact
Phone 844-434-4210
Email Participate-In-This-Study1@its.jnj.com
Participation Criteria
Eligibility Criteria
Inclusion Criteria:
- Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
- Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
- Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations
Exclusion Criteria:
- There are no exclusion criteria for this LTE study
Ages Eligible for Study
Minimum Eligible Age Not available
Maximum Eligible Age Elderly
Age Groups adult, older_adult
Eligible Sexes all
Accepts Healthy Volunteers No
Sampling Method Non-Probability Sample